Robeco Institutional Asset Management B.V. boosted its position in Chemed Corp. (NYSE:CHE) by 58.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 32,393 shares of the company’s stock after buying an additional 11,932 shares during the period. Robeco Institutional Asset Management B.V. owned 0.20% of Chemed Corp. worth $6,626,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Citadel Advisors LLC increased its stake in Chemed Corp. by 195.4% in the first quarter. Citadel Advisors LLC now owns 4,558 shares of the company’s stock worth $833,000 after buying an additional 3,015 shares during the period. Ronald Blue & Co. LLC increased its stake in Chemed Corp. by 2.2% in the first quarter. Ronald Blue & Co. LLC now owns 2,690 shares of the company’s stock worth $491,000 after buying an additional 58 shares during the period. Vanguard Group Inc. increased its stake in Chemed Corp. by 7.5% in the first quarter. Vanguard Group Inc. now owns 1,795,773 shares of the company’s stock worth $328,070,000 after buying an additional 125,018 shares during the period. Glen Harbor Capital Management LLC increased its stake in Chemed Corp. by 11.4% in the first quarter. Glen Harbor Capital Management LLC now owns 624 shares of the company’s stock worth $114,000 after buying an additional 64 shares during the period. Finally, Cambridge Investment Research Advisors Inc. increased its stake in Chemed Corp. by 94.5% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 3,186 shares of the company’s stock worth $582,000 after buying an additional 1,548 shares during the period. 96.96% of the stock is currently owned by institutional investors and hedge funds.

Shares of Chemed Corp. (CHE) opened at 197.29 on Friday. The firm’s 50-day moving average price is $196.43 and its 200-day moving average price is $194.33. The firm has a market capitalization of $3.15 billion, a P/E ratio of 48.94 and a beta of 1.14. Chemed Corp. has a 12-month low of $132.92 and a 12-month high of $216.01.

Chemed Corp. (NYSE:CHE) last posted its earnings results on Tuesday, July 25th. The company reported $2.15 EPS for the quarter, beating the consensus estimate of $1.89 by $0.26. Chemed Corp. had a return on equity of 26.18% and a net margin of 4.16%. The firm had revenue of $415.06 million for the quarter, compared to analysts’ expectations of $407.56 million. During the same period last year, the firm earned $1.80 EPS. The firm’s revenue was up 6.3% compared to the same quarter last year. Equities analysts predict that Chemed Corp. will post $8.21 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 1st. Investors of record on Monday, August 14th will be given a $0.28 dividend. This is a boost from Chemed Corp.’s previous quarterly dividend of $0.26. This represents a $1.12 annualized dividend and a yield of 0.57%. The ex-dividend date of this dividend is Thursday, August 10th. Chemed Corp.’s dividend payout ratio (DPR) is currently 28.07%.

TRADEMARK VIOLATION NOTICE: “Robeco Institutional Asset Management B.V. Purchases 11,932 Shares of Chemed Corp. (CHE)” was posted by Watch List News and is the property of of Watch List News. If you are reading this piece on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.watchlistnews.com/robeco-institutional-asset-management-b-v-purchases-11932-shares-of-chemed-corp-che/1535632.html.

CHE has been the topic of a number of recent research reports. BidaskClub downgraded Chemed Corp. from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. Zacks Investment Research raised Chemed Corp. from a “hold” rating to a “buy” rating and set a $213.00 price objective on the stock in a report on Wednesday, August 23rd. Royal Bank Of Canada reaffirmed a “hold” rating and set a $208.00 price objective on shares of Chemed Corp. in a report on Wednesday, July 5th. Oppenheimer Holdings, Inc. lifted their price objective on Chemed Corp. from $200.00 to $220.00 and gave the company an “outperform” rating in a report on Thursday, July 27th. Finally, TheStreet downgraded Chemed Corp. from a “b+” rating to a “c+” rating in a report on Tuesday, July 25th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $214.00.

In other Chemed Corp. news, Director George J. Walsh III bought 1,000 shares of the stock in a transaction that occurred on Monday, June 26th. The shares were purchased at an average cost of $204.56 per share, for a total transaction of $204,560.00. Following the transaction, the director now directly owns 7,908 shares in the company, valued at $1,617,660.48. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Kevin J. Mcnamara sold 15,000 shares of the firm’s stock in a transaction that occurred on Friday, July 28th. The shares were sold at an average price of $201.16, for a total value of $3,017,400.00. Following the completion of the sale, the insider now owns 173,801 shares in the company, valued at $34,961,809.16. The disclosure for this sale can be found here. 5.32% of the stock is owned by company insiders.

Chemed Corp. Company Profile

Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.

Institutional Ownership by Quarter for Chemed Corp. (NYSE:CHE)

Receive News & Ratings for Chemed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.